Exact Sciences Corp
NASDAQ:EXAS

Watchlist Manager
Exact Sciences Corp Logo
Exact Sciences Corp
NASDAQ:EXAS
Watchlist
Price: 56.81 USD -0.25% Market Closed
Market Cap: 10.7B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one EXAS stock under the Base Case scenario is 75.97 USD. Compared to the current market price of 56.81 USD, Exact Sciences Corp is Undervalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EXAS Relative Value
Base Case
75.97 USD
Undervaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
80
vs Industry
71
Median 3Y
4.4
Median 5Y
5.4
Industry
6.9
Forward
3.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-23.6
Median 5Y
-26.8
Industry
22.9
Forward
-100.5
More Details
33.1
P/OCF
P/OCF
Price to OCF
33.1
vs History
52
vs Industry
4
Median 3Y
49.3
Median 5Y
49.3
Industry
19.7
More Details
118.5
P/FCFE
P/FCFE
Price to FCFE
118.5
vs History
9
vs Industry
5
Median 3Y
44.1
Median 5Y
15
Industry
23.5
More Details
4.5
P/B
P/B
Price to Book Value
4.5
vs History
33
vs Industry
27
Median 3Y
3.7
Median 5Y
4
Industry
2.5
More Details
4.3
EV/S
EV/S
Enterprise Value to Sales
4.3
vs History
82
vs Industry
58
Median 3Y
5.1
Median 5Y
6.1
Industry
7.4
Forward
3.9
More Details
6.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.3
vs History
80
vs Industry
56
Median 3Y
7
Median 5Y
8.5
Industry
9.1
More Details
254.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
254.3
vs History
19
vs Industry
0
Median 3Y
-24
Median 5Y
-39.1
Industry
3.8
Forward
27.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-49.9
Median 5Y
-47.8
Industry
3.8
Forward
-307.2
More Details
37.9
EV/OCF
EV/OCF
Enterprise Value to OCF
37.9
vs History
52
vs Industry
4
Median 3Y
54.9
Median 5Y
54.9
Industry
4.9
More Details
82.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
82.2
vs History
14
vs Industry
0
Median 3Y
-25.5
Median 5Y
-47.9
Industry
3.5
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
47
vs Industry
46
Median 3Y
2.3
Median 5Y
2.5
Industry
4.6
More Details

Multiples Across Competitors

EXAS Competitors Multiples
Exact Sciences Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Exact Sciences Corp
NASDAQ:EXAS
10.7B USD 3.8 -10.5 254.3 -73.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 793 930.5 -165 370.4 -200 812.4 -198 520.9
US
Abbvie Inc
NYSE:ABBV
327.3B USD 5.7 78.8 15 22.2
US
Amgen Inc
NASDAQ:AMGN
149.3B USD 4.4 25.3 13.7 22.6
US
Gilead Sciences Inc
NASDAQ:GILD
135.1B USD 4.7 22.7 9.9 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.6B USD 10.3 -115.5 24.6 25.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 024.8 -516.7 -562.6 -547.6
AU
CSL Ltd
ASX:CSL
120.6B AUD 5.1 28.5 17.5 21.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
65.6B USD 4.6 14.6 13.1 14.7
US
Seagen Inc
F:SGT
39.3B EUR 19.5 -59.8 -64.4 -58.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
38.1B USD 16.2 -141 -630.5 -315.9
P/S Multiple
Revenue Growth P/S to Growth
US
Exact Sciences Corp
NASDAQ:EXAS
Average P/S: 3 163 275.4
3.8
13%
0.3
FR
Pharnext SCA
OTC:PNEXF
34 793 930.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 024.8
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.6
5%
0.9
US
S
Seagen Inc
F:SGT
19.5
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.2
29%
0.6
P/E Multiple
Earnings Growth PEG
US
Exact Sciences Corp
NASDAQ:EXAS
Average P/E: 34
Negative Multiple: -10.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 370.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.8
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.7
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -115.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A N/A
AU
CSL Ltd
ASX:CSL
28.5
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
7%
2.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -141 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Exact Sciences Corp
NASDAQ:EXAS
Average EV/EBITDA: 49.7
254.3
185%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 812.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
13.7
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.6
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -562.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.5
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -630.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Exact Sciences Corp
NASDAQ:EXAS
Average EV/EBIT: 20.1
Negative Multiple: -73.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -198 520.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
22.6
31%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.8
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -547.6 N/A N/A
AU
CSL Ltd
ASX:CSL
21.9
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.7
13%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -315.9 N/A N/A

See Also

Summary
EXAS intrinsic value, competitors valuation, and company profile.
DCF Valuation
EXAS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EXAS stock valuation using valuation multiples.
Wall Street Estimates
EXAS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EXAS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 257,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.